Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
INTERMOLECULAR INC (IMI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/30/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 09/24/2019 |
SC 13D/A
| Raging Capital Management, LLC reports a 0% stake in Intermolecular, Inc. |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/23/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 09/20/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 09/20/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 08/14/2019 |
SC 13D/A
| Merck KGaA reports a 31% stake in INTERMOLECULAR, INC. |
| 08/08/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 08/08/2019 |
8-K
| Quarterly results |
| 07/17/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/28/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/17/2019 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Intermolecular, Electronics for Imaging, El Paso Electric, and Gardner Denver on Behalf of Stockholders and Encourages Investors to Contact the Firm |
| 06/12/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 06/06/2019 |
GN
| ZAYO, CHSP, IMI Merger Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – ZAYO, CHSP, IMI |
| 05/28/2019 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 05/16/2019 |
SC 13D
| Merck KGaA reports a 31% stake in INTERMOLECULAR, INC. |
| 05/16/2019 |
SC 13D
| GAMCO INVESTORS, INC. ET AL reports a 3.6% stake in Intermolecular, Inc. |
| 05/14/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 05/14/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
GN
| BRSS, GDI, EMCI, IMI Shareholder Alert: Halper Sadeh LLP is Investigating Whether the Sale of These Companies is Fair to Shareholders – BRSS, GDI, EMCI, IMI |
| 05/07/2019 |
SC 13D/A
| Raging Capital Management, LLC reports a 29.6% stake in Intermolecular, Inc. |
| 05/06/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/06/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Intermolecular, Inc. (IMI) on Behalf of Stockholders and Encourages IMI Investors to Contact the Firm |
| 05/06/2019 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/06/2019 |
GN
| INTERMOLECULAR, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout |
| 05/06/2019 |
GN
| CHSP, IMI Alert: Halper Sadeh LLP Announces Investigation Into Whether the Sale of These Companies is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ?? CHSP, IMI |
| 05/06/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 6, 2019 Intermolecular, Inc. Delaware 001-35348 20-1616267 3011 N. First Street San Jose, California 95134 Registrant's telephone number, including area code: 582-5700 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement comm...",
"Agreement and Plan of Merger, by and among EMD Group Holding II, Inc., EMD Performance Material Semiconductor Services Corp. and Intermolecular, Inc",
"Form of Support Agreement, by and between EMD Group Holding II, Inc. and certain stockholders of Intermolecular, Inc",
"Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction • Acquisition to strengthen technology offering and diversify performance materials portfolio of Merck KGaA, Darmstadt, Germany • Transaction expected to close in the second half of 2019 San Jose, California, May 6, 2019 - Intermolecular, Inc. has signed a definitive agreement pursuant to which a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, a leading science and technology company, will acquire Intermolecular for $1.20 per share in an all cash transaction, representing an equity value of Intermolecular of approximately $62 million. The acquisition has been unanimously approved by Intermolecular's Board of Directors and the Executive Board of Merck KGaA, Darmstadt, Ge...",
"Letter to Intermolecular employees",
"Letter to Intermolecular customers" |
|
|
|
|